# IV NAD: Infusion Pharmacokinetics, Tolerability, and Status (NAD+) > IV NAD, summarized from the research: infusion pharmacokinetics, tolerability versus IV NR, the rapid plasma clearance of infused NAD+, and its unapproved compounded status. What the controlled data show about infused NAD+: rapid plasma clearance, infusion tolerability versus IV NR, and its standing as an unapproved compounded therapy. ## The gist IV NAD means dripping NAD+ (the cell's energy-handling helper molecule) straight into a vein. It is marketed heavily by wellness clinics, but it has the weakest controlled evidence of any NAD route. Two facts shape the picture. First, infused NAD+ leaves the blood fast — a pilot study found it nearly gone within about two hours. Second, IV NAD+ is a compounded product (mixed to order, not an FDA-approved drug), and one compounded NAD+ injection was recalled by the FDA for bacterial contamination. This page lays out the infusion pharmacokinetics, how it compares to IV NR, and its regulatory standing — each point cited. ## Clearance and Half-Life of Infused NAD+ The question behind most searches for NAD+ half life is simple: how long does it stay around? Infused NAD+ does not linger in the bloodstream. NAD+ itself is not freely taken up intact by most cells, and a pilot study found near-complete plasma removal of infused NAD+ within the first ~2 hours of infusion [12]. That stands in contrast to oral precursors, which raise whole-blood NAD+ gradually over days to weeks, with the elevation persisting through chronic dosing in 8-12 week trials [4]. The pharmacokinetic difference is fundamental: an oral NR or NMN regimen builds and sustains a measured blood-NAD+ rise [4][3], whereas an IV NAD+ bolus is cleared rapidly. This is one reason the controlled-outcome evidence for IV NAD+ remains thin relative to the oral precursors. ## IV NAD+ versus IV NR: the tolerability comparison A 2026 real-world retrospective compared IV NAD+ against IV NR head-to-head. IV NAD+ infusions (500 mg) were associated with moderate-to-severe gastrointestinal symptoms, elevated heart rate, and chest pressure, requiring mean infusion times of about 97 minutes; IV NR infusions (500 mg) caused only mild tingling and required only about 37 minutes on average [12]. The symptoms with IV NAD+ are dose-rate-dependent — running an infusion too fast provokes the GI discomfort, flushing, and chest pressure — which is why the NAD+ infusions in this study were slowed substantially. No serious adverse events were reported, and symptoms resolved upon completing the infusion [12]. ## NAD Injection: What the Limited Controlled Evidence Shows Beyond intravenous infusion, NAD+ is also delivered by subcutaneous and intramuscular injection as a compounded wellness therapy. The controlled evidence for an NAD injection is minimal: there is little peer-reviewed pharmacokinetic data for subcutaneous or intramuscular NAD+, far less than for the oral precursors [4][3] or even for IV infusion [12]. Injectable NAD+ is compounded and not FDA-approved. Like all compounded injectables, it carries contamination risk — reconstituted injectable NAD+ should be kept cold and protected from light, and a compounded NAD+ injection has been subject to an FDA Class I recall for elevated bacterial endotoxin [10]. This digest describes that record; it does not recommend any injection. ## Compounding status and quality risk IV and injectable NAD+ are compounded preparations, not FDA-approved drugs. That distinction carries a documented quality risk: the FDA issued a Class I recall — its most serious category — of a compounded NAD+ injection over elevated bacterial endotoxin [10]. Compounded products are not subject to the same manufacturing oversight as approved drugs, and NAD+ and NMN are hygroscopic and degrade with heat and moisture, so handling matters [10]. The accurate framing is that IV NAD+ is an unapproved compounded wellness therapy with documented quality risks — not an approved treatment, and not something this digest endorses. ## Reported Side Effects and Tolerability in the Studies The reported NAD+ side effects split along the oral-versus-infusion line. In controlled trials, oral NR and NMN were generally well tolerated with no significant adverse-event differences from placebo at the doses tested — see the [doses used in NAD+ research](/dosage) for the specific amounts [4][3]. IV NAD+, by contrast, can cause gastrointestinal discomfort, flushing, elevated heart rate, and chest pressure when infused too quickly; in the 2026 retrospective these symptoms were dose-rate-dependent and resolved on completing the infusion, with no serious adverse events [12]. The most serious documented IV-NAD+ concern is not an acute symptom but a manufacturing one — the FDA Class I endotoxin recall of a compounded NAD+ injection [10]. ## How long do NAD side effects last? In a 2026 real-world retrospective, IV NAD+ infusion symptoms — GI discomfort, chest pressure, elevated heart rate — resolved upon completing the infusion, with no serious adverse events; mean IV NAD+ infusion time was about 97 minutes versus 37 minutes for IV NR [12]. Oral precursor trials reported no significant adverse-event differences from placebo [4]. ## What is an NAD injection? An NAD injection delivers NAD+ by intravenous, subcutaneous, or intramuscular route, typically as a compounded (not FDA-approved) wellness therapy. Controlled evidence is limited; infused NAD+ is rapidly cleared from plasma [12], and compounded products carry contamination risk, including a documented FDA Class I endotoxin recall [10]. ## Does NAD IV actually work? IV NAD+ has the weakest controlled evidence of any NAD route. Infused NAD+ is rapidly cleared from plasma (near-complete removal within ~2 hours in a pilot study) [12], and a 2026 retrospective found IV NR was faster and better tolerated than IV NAD+ [12]. No approved efficacy claim can be made from this evidence. ## Is NAD+ shot worth it? Whether an NAD+ shot is worthwhile is not something this literature can answer. IV/injectable NAD+ is an unapproved compounded therapy with minimal controlled outcome data and documented quality risks, including an FDA Class I endotoxin recall [10]. This digest describes the evidence, not a recommendation. ## When should you inject NAD+? The published literature does not define an evidence-based timing for injecting NAD+. Injectable NAD+ is compounded and not FDA-approved [10], and the controlled pharmacokinetic data are limited [12]; no injection-timing recommendation can be drawn from these studies. --- A flat, color-blocked index of the NAD+ literature — the coenzyme set apart from the precursors NMN and NR that rebuild it, what the trials measured stamped to each study and what they did not left in plain view; no clinic behind the index and nothing here infused, dispensed, or sold.